Treatments

*September 2023* In patients with HER2–mutant non–small cell lung cancer (NSCLC) treated in a cohort of the phase 1a/b BEAMION Lung-1 trial (NCT04886804), treatment with zongertinib (BI 1810631) showed preliminary efficacy signals and acceptable, according to results of the the dose-escalation portion of the study.1 Treatment with zongertinib in the study…

*September 2023* SINGAPORE -- Treatment with the novel antibody-drug conjugate patritumab deruxtecan (HER3-DXd) after progression with an EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy resulted in "clinically meaningful and durable efficacy" in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC), according to the phase II HERTHENA-Lung01 trial. Among the…

*October 2023* This month we have the honor of featuring Dr. Josh Reuss, Assistant Professor of Medicine at Georgetown Lombardi Comprehensive Cancer Center Washington, DC. Dr. Reuss participated in the 2021 EGFR Resisters Research Summit and was a ‘Breakout Session’ winner for his research on A Phase II Open-label Study…

*September 2023* This podcast, for healthcare professionals (HCPs), patients, and patient advocates, is a discussion among a panel of two patients (and co-founders of the patient advocacy group EGFR Resisters, https://egfrcancer.org/) and two oncologists. The objective of the podcast is to explain the importance of biomarker testing for patients with EGFR-mutated non-small…

*August 2023* A supplemental biologics license application (sBLA) seeking the expanded approval of amivantamab-vmjw (Rybrevant) in combination with carboplatin plus pemetrexed for use in the frontline treatment of patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations has been submitted to the FDA.1  …

*July 2023* In this podcast, Dr Tracy Stockley, pathologist and geneticist, University Health Network, and Prof. David Hong, medical oncologist, MD Anderson, come together to provide an introduction to molecular testing. Listen as they discuss: Why identifying genetic alterations is so important How targeted therapies impact outcomes When to use molecular profiling…

*July 2023* Antibody-drug conjugates (ADC) represent one of the most exciting areas of ongoing development for the treatment of patients with non–small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), according to Karen Reckamp, MD, MS, during a presentation at the 24th Annual International Lung Cancer Congress®.1 “This is the…

*June 2023* Lung cancer is a major global health problem, with an estimated 2 million new cases every year and 1.8 million deaths.1 NSCLC is the commonest form and accounts for 85% of all lung cancers.2 Advanced (stage III) and metastatic (stage IV) NSCLC confer the worst prognosis, with 5-year…

*June 2023* In June 2023, Lung Cancer Living Room™ gathered experts such as Dr. Karen Reckamp, Judy Johnson, MBA, and Andrew Ciupek, PhD to discuss and demystify the subject of clinical trials for lung cancer. They started by explaining what clinical trials are, emphasizing that they're not limited to drug…

*September 2023* RARITAN, N.J., Sept. 6, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from the three-arm Phase 3 MARIPOSA-2 study evaluating RYBREVANT® (amivantamab-vmjw), a bispecific antibody targeting epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET), given with and without lazertinib, an oral, third-generation…